BioWorld

March 20, 2009

Cortex Slashing Half its Staff in Latest Round of Belt-Tightening

Cortex Pharmaceuticals Inc. is cutting about half its staff, slashing executive salaries and putting some research projects on the back burner, all in an effort to stay afloat in the troubled economy. (BioWorld Today) Read More

Genome Scan Studies Hold Promise for Cancer Research

Double-Duty Herceptin Variant Challenges Antibody Dogma

Arthritis: How Will it Impact the Biotech and Med-Tech Markets?

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 11, 2025.

3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

BioWorld

3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...

Corestemchemon preps US BLA filing for stem cell ALS therapy

BioWorld Asia

Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...

Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

BioWorld

With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...